Helius Medical Technologies Inc. (HSDT) Soars 5.29% on Reimbursement Wins

On July 2, 2025, Helius Medical Technologies Inc. (HSDT) saw a 5.29% rise in pre-market trading, reflecting a positive sentiment among investors.

Helius Medical Technologies has been actively working on expanding the accessibility and reimbursement of its Portable Neuromodulation Stimulator (PoNS®) Device. The company recently announced that CignaHealth has authorized claims for the PoNS Device, making it the fifth major payer to do so. This follows similar authorizations from Anthem Multiplan and United Healthcare, indicating growing acceptance and validation of the PoNS Device in the healthcare market.

In addition to these reimbursement milestones, Helius Medical Technologies has also made significant strides in clinical research. The PoNSTEP study, which focuses on the long-term therapeutic effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis, has shown promising results. These findings were presented at the Consortium of Multiple Sclerosis Centers Annual Meeting, further bolstering the company's position in the neurotech sector.

Helius Medical Technologies has also been proactive in ensuring compliance with regulatory requirements. The company recently announced that it is compliant with Nasdaq's bid price rule listing criteria, which is crucial for maintaining its listing status. This compliance, along with the company's ongoing efforts to achieve fair market access for its PoNS Device, demonstrates its commitment to operational excellence and regulatory adherence.